IS2439B - Stöðug efnablanda sem felur í sér kirnishliðstæðuog aukefni til frostþurrkunar - Google Patents

Stöðug efnablanda sem felur í sér kirnishliðstæðuog aukefni til frostþurrkunar

Info

Publication number
IS2439B
IS2439B IS5331A IS5331A IS2439B IS 2439 B IS2439 B IS 2439B IS 5331 A IS5331 A IS 5331A IS 5331 A IS5331 A IS 5331A IS 2439 B IS2439 B IS 2439B
Authority
IS
Iceland
Prior art keywords
nucleotide
freeze
drying additives
continuous formulation
formulation
Prior art date
Application number
IS5331A
Other languages
English (en)
Other versions
IS5331A (is
Inventor
Broadhead Joanne
Original Assignee
Astrazeneca Uk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS2439(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Uk Limited filed Critical Astrazeneca Uk Limited
Publication of IS5331A publication Critical patent/IS5331A/is
Publication of IS2439B publication Critical patent/IS2439B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IS5331A 1997-07-11 1999-12-30 Stöðug efnablanda sem felur í sér kirnishliðstæðuog aukefni til frostþurrkunar IS2439B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation
PCT/SE1998/001287 WO1999002542A1 (en) 1997-07-11 1998-06-29 New formulation

Publications (2)

Publication Number Publication Date
IS5331A IS5331A (is) 1999-12-30
IS2439B true IS2439B (is) 2008-11-15

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5331A IS2439B (is) 1997-07-11 1999-12-30 Stöðug efnablanda sem felur í sér kirnishliðstæðuog aukefni til frostþurrkunar

Country Status (35)

Country Link
US (1) US6130208A (is)
EP (1) EP1000079B1 (is)
JP (1) JP4950380B2 (is)
KR (1) KR100786654B1 (is)
CN (2) CN1263533A (is)
AR (1) AR013157A1 (is)
AT (1) ATE340801T1 (is)
AU (1) AU8362598A (is)
BR (1) BR9810703A (is)
CA (1) CA2295628C (is)
CY (1) CY1105805T1 (is)
CZ (1) CZ298110B6 (is)
DE (1) DE69836023T2 (is)
DK (1) DK1000079T3 (is)
EE (1) EE04119B1 (is)
ES (1) ES2273425T3 (is)
HU (1) HU226489B1 (is)
ID (1) ID24716A (is)
IL (2) IL133868A0 (is)
IS (1) IS2439B (is)
MY (1) MY116421A (is)
NO (1) NO329918B1 (is)
NZ (1) NZ502073A (is)
PL (1) PL192768B1 (is)
PT (1) PT1000079E (is)
RU (1) RU2216330C2 (is)
SA (1) SA98190328B1 (is)
SE (1) SE9702680D0 (is)
SI (1) SI1000079T1 (is)
SK (1) SK285766B6 (is)
TR (1) TR200000006T2 (is)
TW (1) TW585764B (is)
UA (1) UA65576C2 (is)
WO (1) WO1999002542A1 (is)
ZA (1) ZA985669B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4986281B2 (ja) * 2004-10-05 2012-07-25 旭化成ファーマ株式会社 補酵素の安定化方法およびその組成物
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
WO2011024933A1 (ja) 2009-08-28 2011-03-03 第一三共株式会社 ３－（ビアリールオキシ）プロピオン酸誘導体
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
BR112012011298B1 (pt) 2009-11-11 2021-12-14 Chiesi Farmaceutici S.P.A. Uso de cangrelor e/ou bivalirudina na preparação de medicamentos e combinação de medicamentos
RU2606845C2 (ru) * 2010-12-10 2017-01-10 СИГМАФАРМ ЛЭБОРЭТОРИЗ, ЭлЭлСи Высокостабильные композиции перорально активных аналогов нуклеотидов или перорально активных пролекарств аналогов нуклеотидов
WO2012109406A1 (en) 2011-02-09 2012-08-16 The Medicines Company Methods for treating pulmonary hypertension
US9700347B2 (en) 2011-08-17 2017-07-11 Samuel Shiber Adaptive rotary catheter for opening obstructed bodily vessels
AU2013381855B2 (en) 2013-03-09 2018-08-02 Chiesi Farmaceutici S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
MA41326A (fr) 2015-01-14 2021-04-28 Chiesi Farm Spa Formulations pharmaceutiques comprenant du cangrelor de haute pureté et leurs procédés de préparation et d'utilisation
WO2018234565A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. METHOD FOR PREVENTING SHUNT THROMBOSIS FROM THE SYSTEMIC-PULMONARY ARTERY
TWI857957B (zh) 2018-06-19 2024-10-11 德商Ｕｃｂ製藥有限公司 吡啶基及吡基-（氮）吲哚磺醯胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (is) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社　ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US5563122A (en) * 1991-12-09 1996-10-08 Asahi Kasei Kogyo Kabushiki Kaisha Stabilized parathyroid hormone composition
SK281309B6 (sk) * 1993-02-10 2001-02-12 Astra Pharmaceuticals Limited N-alkyl-2-substituované adenozíntrifosfátové deriváty, spôsob ich prípravy, farmaceutické prostriedky obsahujúce tieto deriváty a použitie týchto derivátov
CZ306394A3 (en) * 1993-12-14 1995-08-16 Lilly Co Eli Aqueous solution of inclusion complex of benzothiophene derivative with water-soluble cyclodextrins, process of its preparation and a pharmaceutical composition containing thereof
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
JP2001516329A (ja) * 1995-06-07 2001-09-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ポリヌクレオチド複合体の安定化
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
ID21635A (id) * 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku

Also Published As

Publication number Publication date
AR013157A1 (es) 2000-12-13
JP2001509512A (ja) 2001-07-24
PL337970A1 (en) 2000-09-11
MY116421A (en) 2004-01-31
DE69836023T2 (de) 2007-04-12
DK1000079T3 (da) 2006-11-20
WO1999002542A1 (en) 1999-01-21
SE9702680D0 (sv) 1997-07-11
CA2295628A1 (en) 1999-01-21
CZ200083A3 (cs) 2000-06-14
SK183699A3 (en) 2000-07-11
HUP0002622A3 (en) 2002-04-29
ZA985669B (en) 1999-01-11
IL133868A (en) 2010-05-17
KR100786654B1 (ko) 2007-12-21
TW585764B (en) 2004-05-01
ID24716A (id) 2000-08-03
JP4950380B2 (ja) 2012-06-13
AU8362598A (en) 1999-02-08
US6130208A (en) 2000-10-10
SK285766B6 (sk) 2007-07-06
RU2216330C2 (ru) 2003-11-20
NO329918B1 (no) 2011-01-24
PL192768B1 (pl) 2006-12-29
HU226489B1 (en) 2009-03-02
EP1000079B1 (en) 2006-09-27
ES2273425T3 (es) 2007-05-01
SI1000079T1 (sl) 2007-08-31
HUP0002622A2 (hu) 2001-05-28
DE69836023D1 (de) 2006-11-09
NO20000123D0 (no) 2000-01-10
BR9810703A (pt) 2000-08-08
NO20000123L (no) 2000-03-03
HK1026429A1 (en) 2000-12-15
IS5331A (is) 1999-12-30
UA65576C2 (uk) 2004-04-15
KR20010021647A (ko) 2001-03-15
ATE340801T1 (de) 2006-10-15
NZ502073A (en) 2001-09-28
CN1263533A (zh) 2000-08-16
EE04119B1 (et) 2003-08-15
TR200000006T2 (tr) 2000-07-21
EE200000022A (et) 2000-10-16
CZ298110B6 (cs) 2007-06-27
CY1105805T1 (el) 2011-02-02
PT1000079E (pt) 2006-12-29
EP1000079A1 (en) 2000-05-17
SA98190328B1 (ar) 2006-08-15
CN1864696A (zh) 2006-11-22
CA2295628C (en) 2008-07-29
IL133868A0 (en) 2001-04-30

Similar Documents

Publication Publication Date Title
ID22889A (id) Komposisi kopolimer etilena dan penggunaannya
ATE232556T1 (de) Brausezusammensetzungen sowie trockene brausegranulate
NO20001631L (no) 2-metyl-tieno-benzodiazepin formulering
ID28270A (id) Komposisi dan formulasi peptida dan penggunaannya
ID23575A (id) Pirazolopirimidina-pirazolopirimidina dan pirazolotriazina-pirazolotriazina
ID25651A (id) Senyawa-senyawa bisiklo [2.2.1] heptana dan senyawa-senyawa yang terkait
ID27667A (id) Komposisi coklat dan pemakaiannya
ID28336A (id) Soket dan penyumbat listrik yang disempurnakan
ID22957A (id) Senyawa dan penggunaannya
ID29591A (id) Senyawa-senyawa kuinolina dan kuinoksalina
ID28698A (id) Formulasi antiparasit
DE69816084D1 (de) Tintenaufnehmende zusammensetzungen sowie damit beschichtete produkte
ID29543A (id) TURUNAN-TURUNAN OKSAZOL DAN TIAZOL YANG DISUBSTITUSI SEBAGAI AKTIVATOR-AKTIVATOR τhPPAR DAN αhPPAR
ID28166A (id) Formulasi partikulat baru
ID24196A (id) Komposisi dan penggunaan
NL300344I1 (nl) Nucleotide-analogen
ATE207256T1 (de) Steckdübel
ID28752A (id) Metode-metode dan komposisi-komposisi sanitasi
ID26317A (id) Formulasi pelepasan yang diperpanjang
HUP0103636A3 (en) 2-methyl-thieno-benzodiazepine formulation and its use
MY116421A (en) New formulation
ID23258A (id) Penarik pemberian-menyilang dan metodenya
ID19813A (id) Benzotiofen, formulasi yang mengandungnya, dan metodenya
ID21635A (id) Komposisi farmasi untuk pengeringan beku
ID24306A (id) Turunan asam kuinolin-2 karboksilat dan penggunaannya sebagai antagonis asam amino eksitatori